Quest Diagnostics (NYSE: DGX) SVP adds 37 shares through dividend reinvestment

robot
Abstract generation in progress

Mark E. Delaney, SVP & Chief Commercial Officer at Quest Diagnostics (NYSE: DGX), acquired 37 shares of the company’s common stock on April 20, 2026, through a dividend reinvestment plan. This transaction, reported via a Form 4 filing, added to his direct holdings, which now total 11,901 common shares. The acquisition was executed at $194.696 per share and is considered a small transaction under Rule 16a-6.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin